Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.

MLA

Önder, Tuğba, et al. “Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.” Clinical Breast Cancer, vol. 24, no. 6, Aug. 2024, pp. 519–26. EBSCOhost, https://doi.org/10.1016/j.clbc.2024.05.004.

APA

Önder, T., Ateş, Ö., Öner, İ., & Karaçin, C. (2024). Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors. Clinical Breast Cancer, 24(6), 519–526. https://doi.org/10.1016/j.clbc.2024.05.004

Chicago

Önder, Tuğba, Öztürk Ateş, İrem Öner, and Cengiz Karaçin. 2024. “Triglyceride-Glucose Index: A Candidate Prognostic Marker in HR-Positive/HER2-Negative Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors.” Clinical Breast Cancer 24 (6): 519–26. doi:10.1016/j.clbc.2024.05.004.